SMO and cancer: These disappointing trial data dampened the enthusiasm of the field for treating HH-associated cancers by blocking SMO function but at the same time opened up new therapeutic strategies concentrating on the targeted inhibition of the critical oncogenic downstream HH effectors, the GLI zinc-finger transcription factors.